Adenoid cystic carcinoma (ACC) is a rare cancer that most often develops in the salivary glands of the head and neck, although it can arise in other glandular tissues throughout the body.
ACC is unusual because it often grows relatively slowly but can behave persistently over many years. It has a particular tendency to grow along nerves, recur after initial treatment, and sometimes spread to distant organs long after the original cancer was diagnosed.
For localized adenoid cystic carcinoma, treatment commonly involves surgery followed by radiation therapy. Recurrent or metastatic ACC can be more difficult to treat, and clinical trials are playing an increasingly important role in developing better therapies.
Earth Clinic readers have also discussed supplements and alternative approaches for ACC. Complementary therapies may sometimes help with symptoms, nutrition, stress, or treatment side effects, but no natural remedy has been proven to cure adenoid cystic carcinoma.
Adenoid cystic carcinoma develops from secretory glands. It most commonly occurs in the major or minor salivary glands, including glands in the mouth and throat, but ACC can also arise in areas such as the lacrimal glands, trachea, breast, skin, and other sites.
ACC is rare, and its behavior differs from many more common cancers. Some tumors progress slowly for years, while others behave more aggressively.
One characteristic of ACC is perineural invasion, meaning cancer cells can grow along or around nerves. This feature can make complete surgical removal challenging depending on the tumor's location.
Symptoms depend largely on where the tumor develops. Head and neck ACC may cause:
Because ACC can involve nerves, pain, numbness, or weakness may sometimes be important symptoms even when a mass is relatively small.
Diagnosis generally involves imaging and examination of tumor tissue obtained by biopsy or surgery. CT, MRI, PET, or other imaging may be used depending on the location and extent of the disease.
Because ACC is rare and can have distinctive pathological and molecular characteristics, evaluation by clinicians experienced with salivary gland cancers or ACC can be particularly valuable.
For many newly diagnosed patients, surgery is the primary treatment when the tumor can be safely removed.
The goal is to remove the cancer with clear margins while preserving important nerves and surrounding structures whenever possible. This can be difficult when ACC has extended along nerves or developed near critical structures in the head and neck.
Radiation therapy is frequently recommended following surgery, particularly when there is concern about microscopic residual disease, nerve involvement, tumor margins, or other factors associated with recurrence.
Radiation plays an especially important role in ACC because microscopic cancer cells can extend beyond the visible tumor and along nerves.
Modern radiation techniques allow increasingly precise targeting of tumors while limiting radiation exposure to surrounding tissues. Depending on the tumor location and treatment center, options may include intensity-modulated radiation therapy (IMRT), proton therapy, or other specialized radiation techniques.
The most appropriate form of radiation depends on the tumor's location, previous treatments, nearby structures, and other individual factors.
One of the most challenging characteristics of ACC is its potential for late recurrence. A person may remain well for years after treatment before recurrent or metastatic disease is detected.
The lungs are a common site of distant metastasis, although ACC can spread to other organs as well.
Importantly, metastatic ACC does not behave identically in every patient. Some metastatic tumors remain stable or grow very slowly for extended periods, while others progress more rapidly. Treatment decisions therefore depend not simply on whether metastases are present, but also on their location, symptoms, growth rate, and overall disease pattern.
Because ACC can recur many years after apparently successful treatment, long-term surveillance is generally important.
The specific imaging schedule should be individualized according to the original tumor, treatment received, risk factors, and recommendations of the oncology team.
Patients who develop new pain, neurological symptoms, unexplained respiratory symptoms, a new lump, or other persistent changes should report them rather than assuming that a long disease-free interval means recurrence is impossible.
Treating recurrent or metastatic ACC remains challenging. Conventional chemotherapy has generally produced limited and often temporary responses.
Targeted drugs, including medications that affect blood-vessel growth and other molecular pathways, have shown activity in some patients. Immunotherapy has also been studied, although responses in ACC have generally been limited compared with some other cancers.
No single systemic treatment works reliably for everyone with advanced ACC. In some people with slowly progressing metastatic disease, careful observation may even be appropriate for a period of time rather than immediately beginning systemic treatment.
Clinical trials are particularly important for a rare cancer such as ACC because researchers are learning more about the molecular changes that drive different forms of the disease.
Research is investigating targeted therapies, antibody-drug conjugates, immunotherapies, new radiation approaches, and treatments directed at specific molecular characteristics of ACC tumors.
For recurrent, unresectable, or metastatic disease, asking an oncologist about ACC-specific clinical trials can be worthwhile, particularly before assuming that standard chemotherapy is the only remaining option.
Modern cancer care increasingly uses molecular testing to identify genetic or biological characteristics of individual tumors.
ACC research has identified alterations involving pathways such as MYB and NOTCH, among others. Molecular profiling does not guarantee that a matching treatment will be available, but it may sometimes provide information relevant to clinical trials or targeted therapies.
Maintaining good nutrition can become particularly important when ACC or its treatment affects the mouth, throat, salivary glands, or ability to swallow.
Radiation to the head and neck can cause dry mouth, taste changes, mouth soreness, swallowing difficulties, and reduced appetite. These problems can make maintaining weight and muscle more difficult.
Depending on individual needs, helpful strategies may include softer foods, smaller frequent meals, calorie-dense foods, adequate protein, smoothies or other easily swallowed foods, and professional nutrition support.
A dietitian experienced in oncology or head and neck cancer can be especially helpful when eating becomes difficult.
Radiation involving the salivary glands can substantially reduce saliva production. Chronic dry mouth can affect comfort, swallowing, sleep, dental health, and quality of life.
Frequent sips of water, sugar-free gum or lozenges when appropriate, careful dental care, saliva substitutes, and treatments recommended by the oncology or dental team may help.
Dental follow-up is particularly important after head and neck radiation because reduced saliva can substantially increase the risk of tooth decay and other oral complications.
Complementary therapies can be useful when their goal is supporting comfort and quality of life rather than replacing cancer treatment.
Depending on the individual, approaches such as acupuncture, massage, meditation, relaxation exercises, gentle physical activity, and other supportive therapies may help manage symptoms such as pain, stress, fatigue, or treatment-related discomfort.
Acupuncture, for example, has been studied for several cancer-related symptoms, but this should not be confused with evidence that acupuncture treats the cancer itself.
Earth Clinic readers have discussed antioxidants, vitamins, herbs, medicinal mushrooms, hydrogen peroxide, amygdalin or “vitamin B17,” and other alternative approaches for ACC and cancer in general.
Laboratory research can sometimes identify interesting effects of natural compounds on cancer cells, but laboratory activity does not demonstrate that taking the substance treats cancer in humans.
Supplements can also interact with medications or cancer treatments. Patients undergoing radiation, chemotherapy, targeted therapy, or immunotherapy should tell their oncology team about supplements they are taking.
Older alternative cancer literature sometimes promotes hydrogen peroxide as a way to increase oxygen and destroy cancer cells. Earth Clinic has also received reader questions about hydrogen peroxide for ACC.
There is no clinical evidence that drinking, inhaling, injecting, or otherwise administering hydrogen peroxide cures adenoid cystic carcinoma. Concentrated hydrogen peroxide can cause serious injury, and internal use should not be considered a substitute for cancer treatment.
“Vitamin B17” is a name sometimes used for amygdalin, a compound found naturally in the seeds or pits of certain fruits. A partly synthetic form known as laetrile has been promoted as an alternative cancer treatment.
Amygdalin is not recognized as a vitamin, and clinical evidence has not demonstrated that laetrile or amygdalin effectively treats cancer. These products can also release cyanide in the body and can cause serious poisoning.
The older theory that cancer is fundamentally caused by a deficiency of “vitamin B17” has not been established by cancer research.
Physical activity during and after cancer treatment can help maintain strength, mobility, mood, and overall function when tolerated.
The appropriate amount depends on surgery, radiation, fatigue, nutrition, pain, and the person's overall health. Rehabilitation or physical therapy can sometimes help with neck, shoulder, jaw, swallowing, or other functional problems following head and neck cancer treatment.
The long natural history of ACC can create a particular psychological burden. Patients may remain healthy for years while knowing that recurrence can occur later.
Reliable follow-up, an oncology team familiar with ACC, appropriate surveillance, and access to accurate information can help make that uncertainty more manageable.
For recurrent disease, obtaining an opinion from a center experienced in ACC can also be valuable because treatment decisions may differ considerably depending on tumor behavior and location.
The reader posts below include personal experiences and questions about hydrogen peroxide and other alternative approaches for adenoid cystic carcinoma.
Some of these reports were submitted many years ago and reflect cancer theories or treatment claims that have not been supported by subsequent clinical research. They are preserved as reader experiences and should not be interpreted as evidence that a particular remedy treats ACC.
If you have experience with adenoid cystic carcinoma, we invite you to share your story below. Reports are particularly useful when they include the original tumor location, treatments received, recurrence or metastasis history, complementary approaches used, and medically documented outcomes.
